Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD

Inclusion Criteria: * Sign a written informed consent (adults, parents) and assent (adolescents) * Male or female, age 12-50 years. * Diagnosis of Sickle cell disease * Subjects admitted for an acute, painful VOC to be treated/or treated with parenteral opioid analgesia. * Expectancy of need for hospitalization during at least 48 hours. * Be at least 1 year postmenopausal, surgically sterile, or if Women of Child Bearing Potential (WOCBP), e.g. following menarche practicing an effective method of birth control Exclusion Criteria: * Severe hepatic failure/disease, abnormal liver enzyme tests or history of hepatitis B virus (HBV), hepatitis C virus (HCV) * Abnormal conjugated (direct) bilirubin 3 fold above ULN * History of clinically significant bleeding in vital organs * Current clinically significant bleeding, as judged by the investigator * Current use of acetylsalicylic acid (ASA), anti-platelet therapy, anticoagulant therapy * Abnormal coagulation laboratory values * A platelet count \<75,000/µL. * BMI \>35 * Subjects with more than 5 hospitalizations for VOC during the last 6 months * Evidence of acute SCD complications other than VOC at screening * The use of strong opioids for \> 3 consecutive days during the last 15 days before presenting to the hospital * History of chronic drug abuse. * Renal dysfunction * Known infection (positivity) with human immunodeficiency virus (HIV), HBV or HCV. * Significant ECG abnormality * History of a clinically significant drug allergy to heparin, LMWH's, sevuparin, or morphine. * Use of any investigational agent during the 30 days prior to the first dose. * For females: pregnancy, lactating or intention of becoming pregnant * Evidence of clinically significant disorders that might interfere with the study aim or safety of the subject * Any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study.